Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Operating Leases (2023 - 2025)

Beta Bionics' Operating Leases history spans 3 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 6.3% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $5.4 million, down 6.3%, while the annual FY2025 figure was $5.4 million, 6.3% down from the prior year.
  • Operating Leases for Q4 2025 was $5.4 million at Beta Bionics, down from $5.7 million in the prior quarter.
  • Across five years, Operating Leases topped out at $5.7 million in Q4 2024 and bottomed at $3.0 million in Q4 2023.
  • The 3-year median for Operating Leases is $5.4 million (2025), against an average of $5.1 million.
  • The largest annual shift saw Operating Leases surged 90.93% in 2024 before it decreased 6.3% in 2025.
  • A 3-year view of Operating Leases shows it stood at $3.0 million in 2023, then soared by 90.93% to $5.7 million in 2024, then fell by 6.3% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Operating Leases are $5.4 million (Q4 2025), $5.7 million (Q3 2025), and $5.2 million (Q2 2025).